PFIZER LIMITED (PFIZER) AI Stock Analysis

• Market Cap: ₹243.64B
• Dividend Yield: 0.67%
• Average Volume (3M): 2.13K
• Price to Earnings (P/E): 30.1
• Beta (1Y): 0.57
• Revenue Growth: 4.35%
• EPS Growth: 32.89%
• Country: IN
• Employees: 1,721
• Sector: Healthcare
• Sector Strength: 43
• Industry: Drug Manufacturers - General
• EPS (TTM): 41.90
• Shares Outstanding: 45,747,730
• 10 Day Avg. Volume: 1,092
• 30 Day Avg. Volume: 2,130
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹5,367.00
• Price Target Upside: 0.77% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 61 Neutral
• Price Target: ₹5,367.00 ▲(0.77% Upside)

PFIZER LIMITED's strong financial performance is the primary driver of its stock score, supported by robust profitability and cash flow management. However, bearish technical indicators and a high P/E ratio suggest caution, as the stock may be overvalued with weak market momentum.

PFIZER LIMITED Business Overview & Revenue Model

Company Description

Pfizer Limited (PFIZER) is a leading global pharmaceutical corporation engaged in the discovery, development, manufacture, and marketing of healthcare products. The company operates in various sectors, including the development of medicines and vaccines across a wide range of therapeutic areas such as oncology, cardiology, immunology, and infectious diseases. Pfizer is renowned for its innovation in biopharmaceuticals and its contribution to public health with a comprehensive portfolio of products that address some of the most challenging medical conditions.

How the Company Makes Money

Pfizer makes money primarily through the research, development, and sale of pharmaceutical products. The company's revenue streams are driven by its diverse portfolio of patented medications, vaccines, and consumer healthcare products. Key revenue generators include blockbuster drugs, which are high-revenue-generating medications, and vaccines like the COVID-19 vaccine developed in partnership with BioNTech. Pfizer's business model includes collaborating with research institutions, biotechnology firms, and governments to enhance its product offerings. Additionally, the company's extensive global distribution network and strategic partnerships with healthcare providers and pharmacies play a significant role in its revenue generation by ensuring wide accessibility and availability of its products.

PFIZER LIMITED Financial Statement Overview

Summary

PFIZER LIMITED has demonstrated strong profitability with consistent high margins, a robust balance sheet with low leverage, and excellent cash flow management. The company's financials indicate resilience and a competitive standing in the industry.

Income Statement

PFIZER LIMITED has demonstrated strong profitability with a consistent gross profit margin above 60% and an increasing net profit margin, reaching 33.6% in the latest period. The company has shown a healthy EBIT margin of 48.2% and an EBITDA margin of 32.4% for the most recent year. Revenue growth has been somewhat volatile, but there is a positive growth trajectory from the previous year, indicating resilience in the market.

Balance Sheet

The company's balance sheet is robust, with a low debt-to-equity ratio of 0.03, suggesting limited leverage and a strong equity cushion. The return on equity is impressive at 18.2%, indicating efficient use of equity. Additionally, the equity ratio stands at 85.9%, showing a strong capital structure with high asset backing.

Cash Flow

PFIZER LIMITED exhibits a strong cash flow position. With a significant increase in free cash flow, the free cash flow growth rate is 165.5%. The operating cash flow to net income ratio is favorable at 0.86, and the free cash flow to net income ratio is 0.82, suggesting that the company efficiently converts profits into cash.

Breakdown	Mar 2025	Mar 2024	Mar 2022	Mar 2023	Mar 2021
Income Statement
Total Revenue	22.81B	21.93B	26.11B	24.25B	22.38B
Gross Profit	14.71B	13.97B	16.63B	15.51B	14.41B
EBITDA	7.40B	8.24B	8.97B	9.42B	7.92B
Net Income	7.68B	5.51B	6.13B	6.24B	4.98B
Balance Sheet
Total Assets	49.11B	42.29B	39.01B	40.01B	32.66B
Cash, Cash Equivalents and Short-Term Investments	28.01B	20.27B	16.10B	18.82B	10.98B
Total Debt	1.08B	945.40M	1.67B	1.34B	1.06B
Total Liabilities	6.94B	6.33B	10.36B	7.93B	8.73B
Stockholders Equity	42.17B	35.96B	28.64B	32.07B	23.93B
Cash Flow
Free Cash Flow	6.32B	2.38B	6.52B	2.91B	4.10B
Operating Cash Flow	6.60B	2.57B	6.67B	3.56B	4.27B
Investing Cash Flow	-713.40M	-751.30M	-5.75B	-360.50M	-4.69B
Financing Cash Flow	-2.05B	-2.35B	-1.81B	-3.46B	-15.71B

PFIZER LIMITED Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5325.80
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:PFIZER, the sentiment is Positive. The current price of 5325.8 is above the 20-day moving average (MA) of 5187.19, below the 50-day MA of 5408.26, and above the 200-day MA of 4775.43, indicating a neutral trend. The MACD of -92.32 indicates Positive momentum. The RSI at 43.01 is Neutral, neither overbought nor oversold. The STOCH value of 52.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:PFIZER.

PFIZER LIMITED Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALKEM	72 Outperform	₹615.84B	26.96		0.83%	4.49%	11.22%
IPCALAB	66 Neutral	₹347.03B	44.57		0.29%	11.49%	35.00%
ASTRAZEN	66 Neutral	₹216.47B	187.03		0.39%	32.48%	-28.34%
GLENMARK	62 Neutral	₹576.80B	55.08		0.12%	9.39%	―
PFIZER	61 Neutral	₹243.64B	30.13		0.67%	4.35%	32.89%
Sector *	51 Neutral	$7.44B	-0.20	-46.00%	2.26%	22.80%	-2.27%